Share QuidelOrtho Science BYTES Podcast
Share to email
Share to Facebook
Share to X
By QuidelOrtho
4.9
1515 ratings
The podcast currently has 39 episodes available.
The World Health Organization estimates 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection, the main cause of oral herpes, and 491 million people aged 15–49 (13%) worldwide have a herpes simplex virus type 2 (HSV-2) infection, the main cause of genital herpes. Although treatable, most HSV infections are often asymptomatic or unrecognized. Moreover, management of HSV infections is complicated by overlapping clinical presentation of unrelated herpesvirus infections, such as varicella-zoster virus (VZV), requiring differential diagnosis. Innovations in molecular diagnostics continue to play a critical role in the diagnosis and management of these diseases.
About Our Speaker:
Lori Henderson earned a bachelor’s degree in biology from Bucknell University. She began her career in the laboratory working on drug discovery and then transitioned into commercial roles within the biopharma and diagnostics sectors of the life science industry. Lori has direct experience in multiple disease and therapeutic areas and currently focuses on sexually transmitted diseases and women’s health. Within the molecular business unit at QuidelOrtho, Lori is responsible for identifying and helping drive the development of products to meet clinical and patient needs.
Sickle cell disease (SCD) patients are at risk of developing multiple complications from transfusions, including alloimmunization to red blood cell antigens, delayed hemolytic transfusion reactions and hyperhemolysis syndrome (HHS). While HHS is a rare complication of repeat blood transfusions in patients with SCD, clinicians and the laboratory have important roles in its detection and management.
About Our Speaker:
Wally R. Smith, MD, is an experienced implementation scientist and expert in clinical and health services research in sickle cell disease (SCD). He serves as Vice Chair for Research of the Division of General Internal Medicine at Virginia Commonwealth University (VCU) and was Scientific Director of the Center on Health Disparities at VCU. Dr. Smith has authored over 100 publications and served as an investigator on over 50 grants and contracts. He has been principal investigator on 26 federal or foundation-funded grants and contracts including: Pain in Sickle Cell Epidemiology Study (PiSCES), the largest and most detailed adult cohort that changed our understanding of SCD pain in adults and, since 2012, Start Healing in Patients with Hydroxyurea, the first-ever randomized controlled trial of implementation science in SCD.
Six Sigma is a popular way to measure quality. Sigma metrics have been adapted for the clinical laboratory by incorporating observed accuracy, precision and total error allowed (TEa). In vitro diagnostic (IVD) manufacturers have used Six Sigma to assess the quality of their assays using a small number of well-controlled systems to generate the data. QuidelOrtho has developed a novel approach to assess laboratory Sigma metrics for a broad range of assays using data from over 1,300 Vitros® instruments used in clinical labs.
In this podcast, Johanna Miller, data scientist at QuidelOrtho, discusses the value of using real-world data to perform Sigma metric studies and how a lab can use this information.
About Our Speaker:
Johanna Miller holds a bachelor's degree in biomedical engineering from the University of Rochester and a master's in product development and data science from the Rochester Institute of Technology. She spent 10 years developing expertise on Vitros systems and the data it generates, while working in product development. Currently, she focuses on developing new and interesting methods to use data at QuidelOrtho - specifically to bring insights directly to labs using Six Sigma quality scores.
Reference intervals (RIs) are a fundamental decision support tool used by clinicians and lab professionals to interpret laboratory reports and assess an individual’s health status. The establishment of reference intervals, however, can be challenging due to many physiological factors that influence their values and heterogeneities that inherently exist in populations.
In this podcast, Dr. Lindy Crimmins will provide a comprehensive explanation of the influencing factors and evolving methodology of RIs from how they are established to how they are advancing.
About Our Speaker:
Dr. Lindy Crimmins is a Manager of Medical Affairs at QuidelOrtho. She holds a Bachelor’s degree in Chemistry from the University of Wisconsin-Madison and a Medical Degree from the University of Illinois. Her clinical experience spanned from Emergency Medicine to critical care to primary care. Her time in the industry focused on clinical chemistry and point-of-care technical support prior to Medical and Scientific Affairs. Currently, she is responsible for providing medical support for QuidelOrtho’s acute care menu throughout the product lifecycle.
Each year 4.5 million lives are saved by blood transfusions thanks to blood donations. More than 118 million units of blood are donated worldwide every year but less than 10% of people who can donate blood will give. These repeat blood donors enjoy benefits of their own while providing their lifesaving gift. Donating blood burns 650 calories, reduces stress, provides an emotional lift and has physiological benefits.
In this podcast, Dr. Mark A. Levine shares the critical importance of blood donation and how repeat donors enjoy both emotional and physical health benefits.
About Our Speaker:
Dr. Levine is an award-winning physician and lecturer with interests in health professional education, the history of medicine and community empowerment. For 14 years, he served as Chief Medical Officer at the Centers for Medicare and Medicaid Services in Denver. Dr. Levine founded the Colorado Patient Safety Coalition and served as chair of the American Medical Association’s Council on Ethical & Judicial Affairs. He received his bachelor’s degree from Rutgers University and medical degree from Temple University School of Medicine.
Transfusion reactions are adverse events associated with the transfusion of whole blood or one of its components. They range in severity from minor to life-threatening and can occur during a transfusion, termed acute transfusion reactions, or days to weeks later, termed delayed transfusion reactions. Transfusion reactions may be difficult to diagnose as they can present with non-specific, often overlapping symptoms. The most common signs and symptoms include fever, chills, urticaria, and itching. Some symptoms may resolve with little or no treatment. However, respiratory distress, high fever, hypotension, and hemoglobinuria may indicate a more serious reaction. All cases of suspected reactions should prompt immediate discontinuation of the transfusion and notification of the blood bank and treating clinician. Learn in this podcast episode the evaluation and management of transfusion reactions and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.
About our Speaker:
Dr. Aaron Tobian received his medical degrees from Case Western Reserve University. He is highly involved with the transfusion medicine community serving on the Association for the Advancement of Blood and Biotherapies' Board of Directors and is president-elect of the board. Dr. Tobian has authored more than 300 peer-reviewed articles in journals, including The New England Journal of Medicine, JAMA, Blood, and TRANSFUSION, and has been featured on BBC World Service, Today Show, National Public Radio, and USA Today. He is board certified in clinical pathology and blood banking/transfusion medicine and divides his time between research and clinical service.
Alloimmune hemolytic disease of the fetus and newborn (HDFN) may occur when a pregnant woman has an antibody against an antigen on the fetal red cells inherited from the father. Many antibodies to red blood cell antigens can cause HDFN, including those from the ABO, Rh, and other blood group systems. Women can develop antibodies either through previous pregnancy or transfusion.
About our Speaker:
Dr. Genghis Lopez is a Senior Scientist at the Australian Red Cross Lifeblood in Brisbane, Australia. Genghis received his Ph.D. degree from Griffith University, Australia. At Lifeblood, he worked at the Platelet and Granulocyte Reference Laboratory and Red Cell Reference Laboratory and is now part of the Transfusion Science research team that investigates complex red cell blood group variants. He has published several papers in Vox Sanguinis and Transfusion journals reporting novel red cell antigens, novel blood types, and red cell antibodies including several associated with hemolytic transfusion reactions or hemolytic disease of the fetus and the newborn.
According to the American Thyroid Association, as many as 60 percent of those with a thyroid disorder are unaware of their condition, and women are 5 to 8 times more likely than men to develop thyroid disease. If left untreated, thyroid dysfunction increases an individual’s risk for other serious conditions such as cardiovascular disease, infertility and osteoporosis.
Laboratory testing plays an important role to help diagnose and monitor thyroid disease states.
About our Speaker:
Dr. Rea Castro is the Director of Medical Affairs at QuidelOrtho. She holds a Bachelor’s degree in Medical Technology from the University of Santo Tomas and a Medical Degree from the University of the East in the Philippines, and a Master’s in Public Health from Northern Illinois University in the United States. She has experience in both clinical and biotechnology product development covering multiple therapeutic areas. As the head of Medical Affairs, she is responsible for providing medical support of QuidelOrtho’s products throughout the assay lifecycle. Her clinical focus before going into the industry was in Women’s Health.
The fascinating history of the discovery of blood groups goes back to 1900 with the breakthrough that came when Dr. Karl Landsteiner, an Austrian scientist, discovered three human blood groups. These were the A, B, and O blood groups. Two students who worked with Karl Landsteiner discovered the fourth human blood group, the AB. These two were A. van Decastello and A. Sturli. These four blood groups together are what we today know as the ABO blood group system.
In this podcast episode with Dr. Jill Storry, you will learn the fascinating journey behind discovering blood groups and stay up to date on the latest blood groups that have been discovered.
Jill Storry, PhD, Lund University, Sweden
The cybersecurity landscape continues to evolve. Health Care Companies Are the #1 Target for Cyberattacks and Data Breaches. The pace of the release of cybersecurity guidance and regulations for medical devices across the globe has been accelerating. Globally, some regulatory bodies have restricted their guidance to premarket concerns, and others have provided guidelines to include post-market considerations. One of the key tenants of all post-market cybersecurity guidance and regulations is the manufacturer’s responsibility to evaluate and maintain their product cybersecurity continually. This additional level of scrutiny and regulations only increases the need to act now. To prepare for and combat these cyberattacks, healthcare companies must make the necessary investments in people, processes, and technology. A reactive approach to cybersecurity is no longer feasible. It’s time to anticipate and prevent these attacks before they even arrive. Learn in this episode how new, predictive technologies analyze past threats to identify future threats. Ideally, this results in the detection of potentially harmful files or behaviors before an attack is successful.
About Our Speaker:
The podcast currently has 39 episodes available.